ALSO NOTED: Prana chief steps down; Erbitux trial shows added survival time; Encysive makes bid in Europe; and much more...

> Chutes & Ladders: Prana Biotechnology says that CEO Jonas Alsenas has stepped down. Story

> Germany's Merck says that a Phase I/II trial of Erbitux shows the cancer drug may add to the survival time of patients whose cancer had spread beyond their bowels and was beyond surgery when added to standard chemotherapy. Story

> Encysive Pharmaceuticals has made a bid to market its pulmonary arterial hypertension drug Thelin in Europe. Story

> The FDA has given Hoffman-LaRoche approval to use Xeloda for use following colon cancer research. The developer filed for the new indication in August of last year. Story

> San Diego-based Kalypsys and NovImmune have struck a collaboration agreement. Release

> India's Aurobindo has received FDA approval for its AIDS drug Lamivudine. Story

> Cerner is acquiring software-maker Bridge Medical for $11 million. Story

And Finally... Medicare may be planning a big formulary, but some seniors switching from Medicaid to Medicare may find themselves without coverage for badly needed drugs. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.